$SCLN climber $14.69 Nasdaq GM called 8/17/14 $5
Post# of 43
Posted On: 06/15/2016 4:42:31 PM
$SCLN climber $14.69
Nasdaq GM
called 8/17/14 $5.60
Website
Shares Outstanding: 49.91M
Float: 44.47M
% Held by Insiders: 12.48%
% Held by Institutions: 80.80%
Shares Short (as of May 31, 2016): 2.98M
Short Ratio (as of May 31, 2016)3 6.49
Short % of Float (as of May 31, 2016)3 6.05%
Shares Short (prior month): 3.24M
Headlines
SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for oncology, infectious diseases, and cardiovascular disorders in the Peoples Republic of China, the United States, and Hong Kong. Its lead product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as an immune system enhancer. In addition, the company focuses on developing ZADAXIN for the treatment of sepsis. SciClone Pharmaceuticals, Inc. markets and sells ZADAXIN through distribution arrangements, local importers, and distributors. It markets and distributes products, such as DC Bead, Holoxan, Mesna, Endoxan, Methotrexate, Estracyt, Farlutal, Neucardin, ProFlow, Angiomax, and Cleviprex. The company has an agreement with MEDA Pharma GmbH & Co. KG for the development of Tramadol. SciClone Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Foster City, California.
Nasdaq GM
called 8/17/14 $5.60
Website
Shares Outstanding: 49.91M
Float: 44.47M
% Held by Insiders: 12.48%
% Held by Institutions: 80.80%
Shares Short (as of May 31, 2016): 2.98M
Short Ratio (as of May 31, 2016)3 6.49
Short % of Float (as of May 31, 2016)3 6.05%
Shares Short (prior month): 3.24M
Headlines
SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for oncology, infectious diseases, and cardiovascular disorders in the Peoples Republic of China, the United States, and Hong Kong. Its lead product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as an immune system enhancer. In addition, the company focuses on developing ZADAXIN for the treatment of sepsis. SciClone Pharmaceuticals, Inc. markets and sells ZADAXIN through distribution arrangements, local importers, and distributors. It markets and distributes products, such as DC Bead, Holoxan, Mesna, Endoxan, Methotrexate, Estracyt, Farlutal, Neucardin, ProFlow, Angiomax, and Cleviprex. The company has an agreement with MEDA Pharma GmbH & Co. KG for the development of Tramadol. SciClone Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Foster City, California.
(0)
(0)SciClone Pharmaceuticals Inc. (SCLN) Stock Research Links
Scroll down for more posts ▼